Literature DB >> 22432055

Multiple sites of highly amplified DNA sequences detected by molecular cytogenetic analysis in HS-RMS-2, a new pleomorphic rhabdomyosarcoma cell line.

Eiji Takaoka1, Hiroshi Sonobe, Kunihiro Akimaru, Shuji Sakamoto, Taro Shuin, Masanori Daibata, Takahiro Taguchi, Akira Tominaga.   

Abstract

A molecular cytogenetic analysis was performed on HS-RMS-2, a cell line established in this laboratory from a rare pleomorphic type of rhabdomyosarcoma. G-banding and multicolor-FISH analyses revealed that the cells have a complex chromosomal composition. Comparative genomic in situ hybridization (CGH) detected eight highly amplified regions at 1p36.1-p36.2, 1p31-p32, 1q21-q31, 8q12-q21, 8q24-qter, 11q12-q13, 12q13-q14 and 18q12-q22, suggesting the co-existence of multiple amplified oncogenes in these tumor cells. Reverse chromosome painting, using a probe regenerated by microdissection of a long marker chromosome, revealed the native location of three of eight possible genes to be on chromosomes 1p31-32, 12q14 and 18q21. FISH using BAC and cosmid probes revealed amplification of JUN (1p31), MYC (8q24), CCND1 (11q13), INT2 (11q13.3), MDM2 (12q14.3-q15) and MALT (18q21). These findings indicate that at least eight amplified oncogenes may contribute to the pathogenesis of a rare pleomorphic type of rhabdomyosarcoma. This new cell line should prove useful for in vitro preclinical studies of molecularly targeted therapies.

Entities:  

Keywords:  CGH; FISH; Rhabdomyosarcoma; co-amplification; homogeneously staining region; oncogenes

Year:  2012        PMID: 22432055      PMCID: PMC3304565     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  36 in total

1.  Rhabdomyosarcoma: a clinicopathological study and classification of 39 cases.

Authors:  R C HORN; H T ENTERLINE
Journal:  Cancer       Date:  1958 Jan-Feb       Impact factor: 6.860

2.  MYC amplification and polysomy 8 in chondrosarcoma: array comparative genomic hybridization, fluorescent in situ hybridization, and association with outcome.

Authors:  Carl Morrison; Michael Radmacher; Nehad Mohammed; David Suster; Herbert Auer; Susie Jones; Judy Riggenbach; Nicole Kelbick; Gary Bos; Joel Mayerson
Journal:  J Clin Oncol       Date:  2005-12-20       Impact factor: 44.544

Review 3.  Soft tissue sarcomas with complex genomic profiles.

Authors:  Louis Guillou; Alain Aurias
Journal:  Virchows Arch       Date:  2010-02       Impact factor: 4.064

4.  Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma.

Authors:  Brian P Rubin; Koichi Nishijo; Hung-I Harry Chen; Xiaolan Yi; David P Schuetze; Ranadip Pal; Suresh I Prajapati; Jinu Abraham; Benjamin R Arenkiel; Qing-Rong Chen; Sean Davis; Amanda T McCleish; Mario R Capecchi; Joel E Michalek; Lee Ann Zarzabal; Javed Khan; Zhongxin Yu; David M Parham; Frederic G Barr; Paul S Meltzer; Yidong Chen; Charles Keller
Journal:  Cancer Cell       Date:  2011-02-15       Impact factor: 31.743

5.  A new human pleomorphic rhabdomyosarcoma cell-line, HS-RMS-1, exhibiting MyoD1 and myogenin.

Authors:  H Sonobe; T Takeuchi; T Taguchi; K Shimizu; M Furihata; Y Ohtsuki
Journal:  Int J Oncol       Date:  2000-07       Impact factor: 5.650

Review 6.  Cytogenetics and genetics of human cancer: methods and accomplishments.

Authors:  Avery A Sandberg; Aurelia M Meloni-Ehrig
Journal:  Cancer Genet Cytogenet       Date:  2010-12

7.  Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development.

Authors:  Edoardo Missiaglia; Joanna Selfe; Mohamed Hamdi; Daniel Williamson; Gerben Schaaf; Cheng Fang; Jan Koster; Brenda Summersgill; Boo Messahel; Rogier Versteeg; Kathy Pritchard-Jones; Marcel Kool; Janet Shipley
Journal:  Genes Chromosomes Cancer       Date:  2009-06       Impact factor: 5.006

8.  Pathology of fatal rhabdomyosarcoma. Report from Intergroup Rhabdomyosarcoma Study (IRS-I and IRS-II).

Authors:  H Shimada; W A Newton; E H Soule; M S Beltangady; H M Maurer
Journal:  Cancer       Date:  1987-02-01       Impact factor: 6.860

9.  Chromosomal imbalances in pleomorphic rhabdomyosarcomas and identification of the alveolar rhabdomyosarcoma-associated PAX3-FOXO1A fusion gene in one case.

Authors:  Anthony Gordon; Aidan McManus; John Anderson; Cyril Fisher; Syuiti Abe; Takayuki Nojima; Kathy Pritchard-Jones; Janet Shipley
Journal:  Cancer Genet Cytogenet       Date:  2003-01-01

10.  Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.

Authors:  Francesco Marampon; Carmela Ciccarelli; Bianca M Zani
Journal:  Mol Cancer       Date:  2006-08-09       Impact factor: 27.401

View more
  4 in total

Review 1.  Rhabdomyosarcoma: Advances in Molecular and Cellular Biology.

Authors:  Xin Sun; Wei Guo; Jacson K Shen; Henry J Mankin; Francis J Hornicek; Zhenfeng Duan
Journal:  Sarcoma       Date:  2015-09-01

2.  Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls.

Authors:  Ashley R P Hinson; Rosanne Jones; Lisa E S Crose; Brian C Belyea; Frederic G Barr; Corinne M Linardic
Journal:  Front Oncol       Date:  2013-07-17       Impact factor: 6.244

3.  Karyotypic analysis and isolation of four DNA markers of the scleractinian coral Favitespentagona (Esper, 1795) (Scleractinia, Anthozoa, Cnidaria).

Authors:  Rei Kawakami; Takahiro Taguchi; Joshua Vacarizas; Masumi Ito; Takuma Mezaki; Akira Tominaga; Satoshi Kubota
Journal:  Comp Cytogenet       Date:  2022-04-05       Impact factor: 1.800

4.  Identification of homogeneously staining regions by G-banding and chromosome microdissection, and FISH marker selection using human Alu sequence primers in a scleractinian coral Coelastrea aspera Verrill, 1866 (Cnidaria).

Authors:  Takahiro Taguchi; Satoshi Kubota; Takuma Mezaki; Erika Tagami; Satoko Sekida; Shu Nakachi; Kazuo Okuda; Akira Tominaga
Journal:  Comp Cytogenet       Date:  2016-01-22       Impact factor: 1.800

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.